Chronic Pancreatitis Market Is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Kangen Pharmaceuticals, AzurRx BioPharma

Advertisements
DelveInsight Business Research LLP
DelveInsight’s “Chronic pancreatitis (CP) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Chronic pancreatitis (CP), historical and forecasted epidemiology as well as Chronic pancreatitis (CP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Chronic pancreatitis (CP) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Chronic pancreatitis (CP), historical and forecasted epidemiology as well as Chronic pancreatitis (CP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Key Highlights 

Key Companies working in Chronic Pancreatitis include Aptalis Pharma, Digestive Care Inc., Kangen Pharmaceuticals, AzurRx BioPharma, and many others.

Key Therapies included in the Chronic Pancreatitis market include Paricalcitol, Indomethacin, Indomethacin and many others 

Chronic Pancreatitis Overview

Chronic pancreatitis is a progressive inflammatory disorder that leads to irreversible destruction of exocrine and endocrine pancreatic parenchyma caused by atrophy and/ or replacement with fibrotic tissue. Functional consequences include severe abdominal pain, diabetes mellitus, and malabsorption. This activity describes the etiology, pathophysiology, evaluation, and management of chronic pancreatitis and highlights the role of an interprofessional team in the caring and rehabilitation of affected patients.

Chronic pancreatitis is a progressive inflammatory disease of the pancreas that affects both functions of the pancreas. For example, when the exocrine function is affected, patients will present with pancreatic insufficiency, steatorrhea, and weight loss. Pancreatic insufficiency results when greater than 90% of the organ is damaged. The incidence depends on the severity of the disease and can be as high as 85% in severe chronic pancreatitis. On the other hand, impairment of the endocrine function of the pancreas will eventually result in pancreatogenic diabetes (Type 3c diabetes).

Chronic Pancreatitis Epidemiology Insights

A recent epidemiological study in France found an annual incidence of 7.8 per 100,000. Assuming a survival of 15–20 years, the annual prevalence should be between 120 to 143 per 100,000. Overall, our understanding of the epidemiology of CP is poor compared with other illnesses.

Per 100,000 people in the general population, the yearly global incidence of acute pancreatitis is 34 cases, chronic pancreatitis is 10 cases and post-pancreatitis diabetes mellitus is 6 cases.

Click here to learn more about the Chronic Pancreatitis Market Landscape

The Report Covers the Chronic Pancreatitis Epidemiology Segmented by:

Chronic Pancreatitis prevalent cases 

Chronic Pancreatitis incident cases 

Chronic Pancreatitis treatment cases 

Chronic pancreatitis-diagnosed cases 

Chronic Pancreatitis Market Outlook 

The chronic pancreatitis (CP) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic pancreatitis (CP) market trends by analyzing the impact of current Chronic pancreatitis (CP) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Chronic pancreatitis (CP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chronic pancreatitis (CP) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Chronic pancreatitis (CP) market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Chronic Pancreatitis Market

Aptalis Pharma

Digestive Care Inc.

Kangen Pharmaceuticals

AzurRx BioPharma

And many others 

 

Chronic Pancreatitis Therapies Covered and Analyzed in the Report

Paricalcitol

Indomethacin

Creon36

RG1068

And many others 

Learn more about the Key Companies and Emerging Therapies in the Chronic Pancreatitis Market

Table of Contents 

 Key Insights 

 Chronic Pancreatitis Introduction 

 Executive Summary of Chronic Pancreatitis           

 Disease Background and Overview

 Epidemiology and patient population

 Chronic Pancreatitis Emerging Therapies

 Chronic Pancreatitis Market Outlook

 Market Access and Reimbursement of Therapies

 Market Drivers 

 Market Barriers 

 Appendix

 Report Methodology

 DelveInsight Capabilities

 Disclaimer

Learn about the detailed offerings of the report @ Chronic Pancreatitis Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.

Advertisements

Smart public opinion research for everyone.

%d bloggers like this: